Nasdaq

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Monthly Prescribing Reference

Iron Chaperone Granted Fast Track Status for Multiple System Atrophy

Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
Nasdaq

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Seeking Alpha

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
Morningstar

Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy | Morningstar

Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy PR Newswire YOKNEAM, Israel, May 19, 2025 ...
Mena FN

Multiple System Atrophy Market To Reach New Heights In Growth By 2034, Delveinsight Predicts Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance ...

(MENAFN- GetNews) The Key Multiple System Atrophy Companies in the market include - Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis ...
Mena FN

Multiple System Atrophy Market In The 7MM Is Projected To Grow At A CAGR Of 50.60% By 2034, Estimates Delveinsight

DelveInsight's“ Multiple System Atrophy Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Multiple System Atrophy, historical and forecasted ...